Proactive: Racura Oncology advances RNA epigenetics with FTO drug discovery at Monash
Proactive: Racura Oncology advances RNA epigenetics with FTO drug discovery at Monash
Racura CEO Dr Daniel Tillett joins Proactive’s Tylah Tully to discuss the FTO drug discovery program the company has concluded at Monash University’s Fragment Platform (MFP). Watch the full interview below and for the...
ausbiz: Racing ahead – successful trial & board revamp at Racura Oncology
ausbiz: Racing ahead – successful trial & board revamp at Racura Oncology
CEO and MD Dr Daniel Tillett joined ausbiz post the release of September Quarterly Activity Report, reaffirming the company’s strong funding position, clinical pipeline, and noting changes in the Board and Management team. Watch...
Stockhead: HealthInvest 2024: The biotech sector looks in rude health, judging by these five ASX innovators
Stockhead: HealthInvest 2024: The biotech sector looks in rude health, judging by these five ASX innovators
Racura Oncology joins four other biotech companies to present at HealthInvest 2024, hosted by IR Department, Morgans and Stockhead. At the conference, Racura presented the clinical development history of its lead asset bisantrene, and...
Proactive: Racura Oncology completes board renewal to drive next phase of growth
Proactive: Racura Oncology completes board renewal to drive next phase of growth
Racura Executive Chair Dr Peter Smith speaks with Proactive about the recent board changes and the company’s clinical pipeline for its lead drug asset, bisantrene. Read the full report here....
In Stockhead: Racura Oncology races ahead in FY24 with key milestones
In Stockhead: Racura Oncology races ahead in FY24 with key milestones
Racura Oncology is pleased to release the FY24 annual report. Key highlights include: Read the full report via this link....
Racura featured in Stockhead’s Investor Guide: Health & Biotech FY25
Racura featured in Stockhead’s Investor Guide: Health & Biotech FY25
Racura is pleased to be featured in Stockhead’s Investor Guide this year. The Investor Guide showcases strong forces from the Australian health and biotech sector, offering deep insights to ASX investors. In this feature,...
Proactive: Racura Oncology receives positive results from AML trial of Bisantrene
Proactive: Racura Oncology receives positive results from AML trial of Bisantrene
Racura CEO Dr Daniel Tillett speaks with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). Read the article...
The Australian reports the successful conclusion of Racura’s lead drug AML study
The Australian reports the successful conclusion of Racura’s lead drug AML study
The Australian reports the conclusion of Racura’s Phase 1b/2 investigator-sponsored trial of RC110 bisantrene in relapsed or refractory acute myeloid leukaemia patients, conducted at the Chaim Sheba Medical Centre in Israel and led by...
Racura Executive Director on Disrupt Radio
Racura Executive Director on Disrupt Radio
Racura Oncology Executive Director Dr Peter Smith joined Disrupt Radio to discuss building biotech businesses in Australia, what to look out for when investing in biotech businesses, and why Racura’s lead drug bisantrene is...
What’s In Store For 2024: Racura Oncology
What’s In Store For 2024: Racura Oncology
2024 Preview: Racura Oncology (ASX:RAC) from Stockhead on Vimeo. Stockhead’s Ashtyn Hiron sits down with Racura Oncology (ASX:RAC) CEO Daniel Tillett to close the books on 2023 and gain a sneak peek into what’s around the corner. The clinical stage...
